Professor of Medicine, Mayo Medical School
Hematology
Dr. Thomas M. Habermann, MD
|
|
Give Review
Thomas Habermann practices Hematology. He studied medicine at Creighton University School of Medicine. Creighton University School of Medicine is ranked 79 in research and 78 in primary care medicine He over the years received 2 awards: "America's Top Doctors" and "America's Top Doctors for Cancer". Thomas Habermann is a published doctor. He has 100 publications published. The most current publication "Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes." He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin Lymphomas: Eastern Cooperative Oncology Group Protoco...
- Large B-cell transformation in nodular lymphocyte predominant Hodgkin Lymphoma: forty-year experience from a single institution.
- Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
- Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin Lymphoma in the modern era.
- Personalized risk prediction for event-free survival at 24 months in patients with diffuse large b-cell Lymphoma.
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell Lymphoma.
- Hodgkin transformation of chronic lymphocytic Leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma.
- Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Resu...
- Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular Lymphoma in the immunochemotherapy era: a report from the University of Iowa...
- A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin Lymphoma.
- Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin Lymphoma.
- BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular Lymphoma.
- PARANEOPLASTIC SARCOID-LIKE REACTIONS AND THE EYE.
- Elevated serum levels of IL-2R, IL-1RA and CXCL9 are associated with a poor prognosis in follicular Lymphoma.
- Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region.
- Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell Lymphoma.
- Clinical characteristics and healthcare utilization of patients with multicentric Castleman Disease.
- Rituximab Extended Schedule or Re-Treatment Trial for Low-Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402.
- Medical History, Lifestyle, and Occupational Risk Factors for Hairy Cell Leukemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project.
- Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project.
- Widespread use of complementary and alternative medicine among non-Hodgkin Lymphoma survivors.
- ALK-negative anaplastic large cell Lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.
- The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell Lymphoma and baseline bone marrow involvement.
- Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outc...
- Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin Lymphoma.
- GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.
- A multicentre study of primary breast diffuse large B-cell Lymphoma in the rituximab era.
- Clinical epidemiology and treatment patterns of patients with multicentric Castleman Disease: results from two US treatment centres.
- Lymphoma-associated skin cancer: incidence, natural history, and clinical management.
- Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma.
- Cytokine gene polymorphisms and progression-free survival in classical Hodgkin Lymphoma by EBV status: Results from two independent cohorts.
- Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter Analysis.
- Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin Lymphoma who received prior stem cell transplantation.
- Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-Cell or natural killer Cell neoplasms: an East...
- Diffuse large B-cell lymphoma (Richter Syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients.
- Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Researc...
- CXCR5 polymorphisms in non-Hodgkin Lymphoma risk and prognosis.
- A phase i trial of immunostimulatory CpG 7909 oligodeoxynucleotide and (90) yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-hodgkin Lymphoma.
- Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era.
- Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Co...
- The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin Lymphoma.
- Endobronchial ultrasound and lymphoproliferative Disorders: a retrospective study.
- The clinical spectrum of Castleman's Disease.
- Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell Lymphoma.
- Secondary Epstein-Barr virus associated lymphoproliferative disorder developing in a patient with angioimmunoblastic T cell Lymphoma on vorinostat.
- Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell Lymphoma patients.
- New developments in the management of diffuse large B-cell Lymphoma.
- Secondary intramedullary spinal cord non-Hodgkin's Lymphoma.
- Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin Lymphoma.
- Activity of Topotecan 21-Day Infusion in Patients with Previously Treated Large Cell Lymphoma: Long-term follow-up of an Eastern Cooperative Oncology Group Study (E5493).
- The Absolute Monocyte Count is Associated with Overall Survival in Patients Newly Diagnosed with Follicular Lymphoma.
- A genome-wide meta-analysis of nodular sclerosing Hodgkin Lymphoma identifies risk loci at 6p21.32.
- LMO2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell Lymphoma in the pre-rituximab era.
- Food-frequency questionnaire based estimates of total antioxidant capacity and risk of non-hodgkin Lymphoma.
- Cardiac Toxicity Associated with Bevacizumab (Avastin) in Combination with CHOP Chemotherapy for Peripheral T Cell Lymphoma in ECOG 2404 Trial.
- Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory Lymphomas.
- Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cel...
- Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell Lymphoma.
- GWAS of Follicular Lymphoma Reveals Allelic Heterogeneity at 6p21.32 and Suggests Shared Genetic Susceptibility with Diffuse Large B-cell Lymphoma.
- Design and validity of a clinic-based case-control study on the molecular epidemiology of Lymphoma.
- Patients with celiac disease and B-cell Lymphoma have a better prognosis than those with T-cell Lymphoma.
- Germline variation in apoptosis pathway genes and risk of non-Hodgkin's Lymphoma.
- Vitamin D insufficiency and prognosis in non-Hodgkin's Lymphoma.
- Diagnosis and management of Waldenström Macroglobulinemia: Mayo stratification of Macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
- Smoking, alcohol use, obesity, and overall survival from non-Hodgkin Lymphoma: a population-based study.
- The treatment of recurrent/refractory chronic lymphocytic Leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of C...
- A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin Lymphoma.
- Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology G...
- Antioxidant intake from fruits, vegetables and other sources and risk of non-Hodgkin's Lymphoma: the Iowa Women's Health Study.
- Statin use and prognosis in patients with diffuse large B-cell Lymphoma and follicular Lymphoma in the rituximab era.
- Complementary and alternative medicine use among long-term Lymphoma survivors: a pilot study.
- Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin Lymphoma.
- Association of resident fatigue and distress with perceived medical errors.
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports ...
- Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent Lymphoma: results of the randomized p...
- Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell Lymphoma.
- Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's Lymphoma.
- Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's Lymphoma.
- Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell Lymphoma patients in the pre-rituxima...
- mTOR inhibitor monotherapy is insufficient to suppress viremia and Disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD).
- SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell Lymphoma.
- Posttransplant lymphoproliferative Disorders.
- Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin Lymphoma.
- Prognostic significance of host immune gene polymorphisms in follicular Lymphoma survival.
- A prospective study of the relationship between medical knowledge and professionalism among internal medicine residents.
- Treatment of benign orbital pseudoLymphomas with the monoclonal anti-CD20 antibody rituximab.
- Epstein-Barr virus infection as a complication of transplantation of a nerve allograft from a living related donor. Case report.
- Antibody therapy in aggressive Lymphomas.
- A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untr...
- Education scholarship.
- Splenectomy, interferon, and treatments of historical interest in hairy cell Leukemia.
- Association of perceived medical errors with resident distress and empathy: a prospective longitudinal study.
- Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell Lymphoma.
- Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.
- Prospective study of survival outcomes in Non-Hodgkin's Lymphoma patients with rheumatoid arthritis.
- Current status of medical grand rounds in departments of medicine at US medical schools.
- Natural killer/T-cell Lymphoma with ocular and adnexal involvement.
- Adult B-cell Lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior.
- Genetically predicted longer telomere length is associated with increased risk of B-cell Lymphoma subtypes.
Schools
Creighton University School Of Medicine
Mayo Clinic Rochester
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Burkitt's Lymphoma
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
Education
-
Mayo School of Graduate Medical Education -
Creighton University School of Medicine
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1790757672 | |
| NPPES Provider LastName | HABERMANN | |
| NPPES Provider FirstName | THOMAS | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 172.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 11.0 | |
| Percent Opioid Claims | 6.4 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1790757672 |
| Last Name Of The Provider | HABERMANN |
| First Name Of The Provider | THOMAS |
| View All |
Similar Doctors
|
|
Dr. Jeremy T. Larsen, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gita Thanarajasingam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick B. Johnston, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William J. Hogan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aref Al-Kali, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lisa M. Baumann Kreuziger, MD |
|
|
Dr. Robert A. Kyle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rattiya Cheewakriangkrai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shernan G. Holtan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul J. Kurtin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Manish Kohli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aneel A. Ashrani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Neil E. Kay, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jessemy D. Neiger, MD |
|
|
Dr. Robert R. McWilliams, MD |
|
|
Dr. David A. Cook, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erin L. Schenk, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stefan F. Cordes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amie E. Jackson, MD |
|
|
Dr. Alexis D. Leal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ben Y. Zhang, MD
This Doctor is OpenDoctor Recommended.
|